Medigene AG (ETR:MDG1)’s share price traded up 0.4% on Wednesday . The company traded as high as €3.91 ($4.60) and last traded at €3.90 ($4.58). 2,535 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 306,207 shares. The stock had previously closed at €3.88 ($4.56).
The firm has a market cap of $101.08 million and a P/E ratio of -3.50. The company has a quick ratio of 3.16, a current ratio of 3.23 and a debt-to-equity ratio of 9.70. The stock’s 50 day simple moving average is €3.92.
About Medigene (ETR:MDG1)
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies.
Recommended Story: What are the Benefits of Index Funds?
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.